Tesamorelin: A Stabilised GHRH Analog

Tesamorelin belongs to the same family as CJC-1295 and sermorelin — all are engineered forms of growth hormone-releasing hormone — but it takes a different approach to the same stability problem.

The parent sequence

Native GHRH is a 44-residue peptide. The first 29 residues carry full receptor activity, which is why several analogs are built on GHRH(1-29). Tesamorelin is unusual in retaining the full 44-residue length rather than truncating.

The modification

A trans-3-hexenoyl group is attached at the N-terminus. The N-terminal region is where dipeptidyl peptidase-4 cleaves, so occupying it with an acyl group blocks the principal degradation route while leaving the receptor-binding determinants intact.

This is a different strategy from the two other common approaches. CJC-1295 uses amino acid substitutions to resist cleavage, optionally combined with an albumin-binding group; sermorelin is essentially unmodified GHRH(1-29) and is correspondingly short-lived. Comparing the three is a clean illustration of how the same stability problem admits several solutions — see peptide half-life and how analogs extend it.

Why the distinction matters experimentally

GHRH receptor signalling is pulsatile in vivo. Analogs with different exposure profiles therefore probe different questions, and an experimental design written for one is not transferable to another. Treating GHRH analogs as an interchangeable class is the most common design error in this area.

Literature: PubMed and the broader GHRH analog literature.

Why the full 44 residues

GHRH(1-29) carries full receptor activity, so truncation is the obvious economy and most analogs take it. Retaining the complete 44-residue sequence is therefore a deliberate choice rather than an omission, and it has consequences worth understanding.

The C-terminal region beyond residue 29 does not contribute to receptor activation, but it does contribute to the peptide’s conformational behaviour in solution. Longer GHRH sequences show greater helical propensity, and the helix is the receptor-bound conformation. Whether that translates into a measurable potency difference depends on the assay, but it does reliably change how the peptide behaves physically — solubility, aggregation propensity and adsorption all differ between a 29-mer and a 44-mer of the same family.

The practical implication is that tesamorelin and GHRH(1-29) analogs should not be treated as the same molecule at different lengths for handling purposes. They are not equally forgiving in the vial.

N-terminal acylation versus the alternatives

Dipeptidyl peptidase-4 cleaves GHRH between residues 2 and 3, and that single event inactivates the peptide. Three strategies address it, and each has a distinct signature in vitro:

• N-terminal acylation (the tesamorelin approach). A short unsaturated acyl group occupies the region the protease needs. It adds no albumin dependence, so in vitro potency measured with and without serum should be broadly consistent — which makes it a comparatively clean molecule to characterise.
• Amino acid substitution (the CJC-1295 approach). Non-natural residues at the cleavage site and at oxidation-prone positions. Also albumin-independent unless a binding group is added.
• Albumin conjugation (CJC-1295 with DAC). A maleimide group binds cysteine-34 of albumin covalently, creating a circulating reservoir. In vitro, that same binding sequesters a fraction of the compound in any serum-containing assay, so apparent potency drops relative to a serum-free measurement. Comparing a DAC analog against an unmodified one in serum-containing medium systematically understates the former.

The distinction between the DAC and no-DAC forms is covered in CJC-1295 DAC vs no DAC.

Pulsatility, and why exposure profile is the experiment

Growth hormone release is pulsatile, and the downstream response depends on the pattern of receptor occupancy as much as on total exposure. Continuous occupancy drives GRK phosphorylation, arrestin recruitment, internalisation and desensitisation at the GHRH receptor, so a long-acting analog is not simply a short-acting one that lasts longer — it produces a qualitatively different stimulus.

This has a direct bearing on study design. Matching two analogs on total exposure and matching them on peak concentration are different experiments that can yield opposite-looking results from the same pair of compounds. Whichever was chosen has to be stated. Similarly, a single blood sample measures the sampling schedule as much as the compound; capturing pulses requires frequent serial sampling, and IGF-1 is the usual integrated alternative precisely because it smooths the pattern away.

Readouts

• cAMP accumulation at the GHRH receptor — the mechanistically correct assay for this class, since GHRHR is Gs-coupled. Running a GHRH analog in a calcium assay and reporting nothing is a category error rather than a finding; the calcium readout belongs to the secretagogue receptor.
• Growth hormone release from primary pituitary cell culture. Standard in vitro measure. Dispersed cells carry no hypothalamic input, so somatostatin tone is absent and part of the in vivo distinction between compound classes disappears.
• Perifusion. Continuous-flow culture allowing timed exposure and washout — substantially more informative than static culture wherever kinetics are the point.
• IGF-1. Less noisy than growth hormone, but an integrator: it will not distinguish a pulsatile pattern from a continuous one delivering the same total.
• Additivity with a secretagogue. Because GHRHR and GHS-R1a are separate receptors with separate second messengers, co-administration produces a response larger than either alone. That additivity is a useful mechanistic control on receptor assignment. See GHRH analogs and growth hormone secretagogues compared.

Analytical characterisation of a long acylated peptide

A 44-residue acylated sequence raises questions a short peptide does not.

• Calculated mass must include the acyl group. Omitting it is a common arithmetic error, and it makes an otherwise correct certificate look wrong — or a wrong one look right.
• RP-HPLC purity with gradient, column and wavelength stated. Deletion sequences in a 44-mer are numerous and elute close to the main peak; a steep gradient hides them. This is exactly the case where a headline purity figure without conditions is uninformative.
• Aggregation state. Long amphipathic sequences aggregate, and an aggregated stock reports a wrong concentration in every downstream assay. Size-exclusion chromatography or dynamic light scattering reveals it; a cell assay does not.
• Net peptide content. More consequential the longer the peptide, since counterion mass scales with charged residue count. See net peptide content explained.
• Oxidation. Methionine and tryptophan in a long sequence give more oxidation sites; a plus-16 mass satellite on the MS trace is the signature. See deletion, truncation and oxidation impurities.

Reconstitution and storage in practice

• Wet the cake before mixing. Add solvent slowly down the vial wall and let it stand. Directing a stream at a lyophilised cake of a long peptide is a reliable way to produce aggregate.
• No vortexing or sonication. Both shear and both promote aggregation in long sequences. Gentle inversion, and patience.
• Near-neutral buffer unless solubility dictates otherwise; check for clarity against a dark background before use, since fine aggregate is easy to miss.
• Aliquot immediately and never thaw a tube twice.
• Low-binding plasticware at low working concentrations, where surface adsorption of a long peptide is a real loss.
• Protect from light and keep solution age, not vial age, as the variable you track.

Solvent selection is covered in choosing a reconstitution solvent, aliquoting practice in aliquoting and vial entry, and general conditions in storage and stability.

Comparing the three GHRH analogs

Sermorelin, CJC-1295 and tesamorelin are the three that recur, and the useful summary is that they differ on two axes rather than one: how cleavage is blocked, and whether albumin is involved.

• Sermorelin — essentially unmodified GHRH(1-29). Short-lived, and therefore the closest available approximation to a native pulse.
• CJC-1295 without DAC — substituted for cleavage resistance, no albumin binding. Longer than sermorelin, still short relative to the DAC form.
• CJC-1295 with DAC — adds covalent albumin binding and a much longer exposure profile, with the in vitro caveat described above.
• Tesamorelin — full-length, N-terminally acylated, cleavage-resistant without albumin dependence.

Any experiment comparing them has to hold the exposure question explicit, or the comparison measures pharmacokinetics while appearing to measure pharmacology.

Terms used here

• GHRH — growth hormone-releasing hormone; 44-residue hypothalamic peptide.
• GHRH(1-29) — the N-terminal fragment carrying full receptor activity.
• GHRHR — the receptor; class B1 GPCR, Gs-coupled, cAMP readout.
• DPP-4 — dipeptidyl peptidase-4; cleaves between residues 2 and 3 and inactivates the peptide.
• DAC — drug affinity complex; the albumin-binding maleimide group on one CJC-1295 form.
• Somatotroph — the anterior pituitary cell type that synthesises and secretes growth hormone.
• Perifusion — continuous-flow culture permitting timed exposure and washout.

Handling

At 44 residues tesamorelin is longer than most peptides in a research catalogue, and longer sequences are more prone to aggregation on reconstitution. Add solvent gently down the vial wall, allow the cake to wet before mixing, and avoid vortexing or sonication. See choosing a reconstitution solvent.

Product: Tesamorelin 10mg; related compounds in GHS compounds, and background in GHRH analogs vs secretagogues.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.